Betta Pharmaceuticals Co (SZSE:300558) 3-Year Revenue Growth Rate : 8.40% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Betta Pharmaceuticals Co 3-Year Revenue Growth Rate?

Betta Pharmaceuticals Co's Revenue per Share for the three months ended in Mar. 2024 was ¥1.72.

During the past 12 months, Betta Pharmaceuticals Co's average Revenue per Share Growth Rate was 12.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was 8.40% per year. During the past 5 years, the average Revenue per Share Growth Rate was 13.90% per year. During the past 10 years, the average Revenue per Share Growth Rate was 14.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Betta Pharmaceuticals Co was 28.20% per year. The lowest was 6.60% per year. And the median was 12.40% per year.

Competitive Comparison of Betta Pharmaceuticals Co's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Betta Pharmaceuticals Co's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Betta Pharmaceuticals Co's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Betta Pharmaceuticals Co's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Betta Pharmaceuticals Co's 3-Year Revenue Growth Rate falls into.

Betta Pharmaceuticals Co 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Betta Pharmaceuticals Co (SZSE:300558) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Betta Pharmaceuticals Co 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Betta Pharmaceuticals Co's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Betta Pharmaceuticals Co (SZSE:300558) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Betta Pharmaceuticals Co Ltd (SZSE:300558) » Definitions » 3-Year Revenue Growth Rate

Traded in Other Exchanges

N/A

Address

No.355, Xingzhong Road, Yuhang Economic and Technological Development Zone, Zhejiang Province, Hangzhou, CHN

Website

http://www.bettapharma.com

Betta Pharmaceuticals Co Ltd is a hi-tech pharmaceutical enterprise focuses on research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates through China.

Executives

Wang Jia Bing	Directors, executives
Ding Lie Ming	Directors, executives
Cai Wan Yu	Executives

Betta Pharmaceuticals Co (SZSE:300558) Headlines

No Headlines